RxDoctor Payments Data

Allan Wicks, MD

Cardiovascular Disease · Casper, WYNPI 1497792402

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 79.1% of it on its own, with 8 other manufacturers making up the rest.

$1,305in general payments, 2019–2025

Across 62 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Shockwave Medical, Inc$102
  • Novartis$41
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$37
  • Merck$22
  • Terumo Medical Corporation$22
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$1,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,305 in reported general payments places this provider in the 55th percentile of 22 cardiovascular disease providers in Wyoming.

See all cardiovascular disease providers in Wyoming

Medicare billing

Part B allowed, 2024
$507,479
Medicare patients
2,207
Services billed
7,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban550$477,728
XareltoRivaroxaban47$49,127
EntrestoSacubitril/Valsartan26$41,254
Flecainide Acetate165$6,842
Praluent PenAlirocumab11$5,103
Atorvastatin Calcium548$4,723
Metoprolol Succinate386$4,307
Potassium Chloride184$3,385
Amlodipine Besylate336$2,522
Nebivolol Hcl24$2,391
Losartan Potassium261$2,306
Digoxin103$1,897
Carvedilol226$1,742
SotalolSotalol Hcl86$1,621
Warfarin Sodium169$1,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$41$41,25426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 22 cardiovascular disease providers in Wyoming.

Other cardiovascular disease in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →